logo
episode-header-image
Oct 2024
23m 58s

Hot shot: the wider promise of weight-lo...

The Economist
About this episode

First they treated diabetes. Then obesity. Now GLP-1 drugs are being tested on a range of other diseases too. Though the US economy is roaring, many Americans are glum about its prospects. How could that affect the election (9:02)? And our podcast on why Chinese migrants are making perilous journeys through the jungle to reach America (16:55).


Listen to what matters most, from global politics and business to science and technology—Subscribe to Economist Podcasts+


For more information about how to access Economist Podcasts+, please visit our FAQs page or watch our video explaining how to link your account. 




Hosted on Acast. See acast.com/privacy for more information.

Up next
Today
Brave New whirl: Turkey’s opposition overhaul
An ousted former opposition leader started a new party—called the New Party. We assess its chances at the ballot box, and under President Recep Tayyip Erdogan’s thumb. A surrogacy scandal in Germany has prompted a government reshuffle, with Chancellor Friedrich Merz left holding ... Show More
20m 27s
Yesterday
Burning questions: a more fire-prone world
Wildfires in France and Spain are only growing worse by the day. We examine what can be done as a future of more fires, and worse ones, becomes more assured. A dig into data on women at work shows several indicators starting to move in the wrong direction. And the American cities ... Show More
24m 17s
Jul 27
Cockroaches 1, Modi 0: India’s remarkable protests
The resignation of India’s education minister was a stunning capitulation by Prime Minister Narendra Modi’s government. The Cockroach Janta Party, a fast-growing youth movement, has the upper hand for now. So-called macro trading is hard: even with advance knowledge of events, ne ... Show More
22m 34s
Recommended Episodes
Dec 2024
068 | The weight is over: How GLP-1 treatments are reshaping pharma and beyond
Weight-loss drugs have become a golden formula for pharma growth. In this episode we speak to Sector Advisor Maria Latorre and Senior Economist Michaela Grimm about how GLP-1 treatments like Ozempic and Wegovy are reshaping the industry, and the risks that lie ahead. SHOWNOTES: • ... Show More
11m 16s
Dec 2024
A checkup on weight-loss drugs
What started as a story about Hollywood waistlines has become a global phenomenon. Weight loss drugs are becoming more and more mainstream a few years after making their dramatic debut. On this weekend episode of Reuters World News, our health reporters weigh in on the impact of ... Show More
20m 17s
Feb 2024
The obesity drug craze is entering its next phase
Eli Lilly and Novo Nordisk can’t keep up with demand for their weight loss medications. In this Viewsroom podcast, Breakingviews columnists discuss the hype among celebrities, the different approaches to prescribing them in the US and Europe, and how they can reshape the world. V ... Show More
22m 46s
Nov 2025
The end of dieting
The Trump administration is making GLP-1s more affordable. This class of drugs seems to have forever changed the game on diet and exercise for Americans. This episode was produced by Miles Bryan, edited by Jolie Myers, fact-checked by Laura Bullard, engineered by Patrick Boyd and ... Show More
25m 50s
Apr 2024
Money Talks: Why weight-loss drugs will reshape the world
More than 1bn people around the world are obese. That means there should be extraordinary demand for drugs to cure or mitigate the condition. Novo Nordisk is now Europe’s most valuable company and Eli Lilly’s market value has more than doubled. Both make the “miracle” drugs that ... Show More
36m 59s
Apr 2024
Money Talks: Why weight-loss drugs will reshape the world
<p>More than 1bn people around the world are obese. That means there should be extraordinary demand for drugs to cure or mitigate the condition. Novo Nordisk is now Europe’s most valuable company and Eli Lilly’s market value has more than doubled. Both make the “miracle” drugs th ... Show More
36m 59s